Video: Agustín Seijo presents FluoTB at the Santander X Global Awards
Our CEO, Agustín Pablo Seijo, shares the vision behind FluoTB, the low-cost tuberculosis diagnostic tool we are developing.
The recognition
HerelleX was recognized at the Santander X Global Awards, held during MWC Barcelona 2026.
Tuberculosis today
In 2024, 10.7 million people fell ill with tuberculosis worldwide, including 1.2 million children. The disease caused 1.23 million deaths, of which about 174,000 were among children under 15: roughly one child every three minutes. More than 80% of cases and deaths occur in low- and middle-income countries (source: WHO Global TB Report 2025).
The diagnostic gap
That same year, 8.3 million people were diagnosed: an estimated 2.4 million cases went undiagnosed. In addition, only 54% of people diagnosed were first tested with a WHO-recommended rapid test. A low-cost, fast and accessible tool can help close that gap.
About FluoTB
We are developing FluoTB, a low-cost diagnostic tool based on engineered mycobacteriophages. Its goal is to make TB detection faster and more accessible, especially in low-resource and high-burden regions.
The video
In the video, our CEO, Agustín Pablo Seijo, talks about the project and the vision behind FluoTB.
